Please log in for more information
The field of cancer immunotherapy has expanded rapidly in recent years with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches such as cancer vaccines and chimeric antigen receptor (CAR) therapy. Despite the dramatic and durable responses seen in many patients, our understanding of the immune response to cancer is still limited, and we cannot reliably predict who will or will not benefit from these new interventions. To better stratify patients for immunotherapy treatments, the series of events and biomarkers involved in the cancer immunity cycle need to be better understand(1-3). In addition, spatially mapped expression data at the single-cell level is crucial to understanding the cellular organization and cell-to-cell interactions in the tumor and its complex microenvironment (TME).More information
Company Information:
Advanced Cell Diagnostics’ RNAscope® Technology is an in situ hybridization (ISH) assay for detection of target RNA within intact cells. The assay represents a major advance in RNA ISH approaches with its proprietary probe design to amplify target-specific signals but not background noise from non-specific hybridization. Unique to this technology, RNAscope® delivers quantitative, sensitive and specific molecular detection of RNA species on a cell-by-cell basis with morphological context in a single assay. This enables researchers to visualize which genes are expressed, localize where they are expressed, and quantify the level of expression.Contact Information:
Advanced Cell Diagnostics SRLVia Calabria, 15
20090 Segrate (Milano) Italy
email: order_europe@acdbio.com
Phone: +39-02-95 360 323
